Alterations of the LFTs both with a cytolysis pattern and sometimes with predominant cholestasis
Dear Mr. Shah,
Perhaps the following links may be useful:
https://www.jcehepatology.com/article/S0973-6883(20)30027-X/fulltext
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30132-1/fulltext
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30126-6/fulltext
https://www.karger.com/Article/FullText/508116
Happy Reading!
Given that COVID-19 may include stomach and bowel symptoms, gastroenterologists may consider the coronavirus illness when evaluating patients with GI complaints along with upper respiratory symptoms, researchers said.
Moreover, patients with inflammatory bowel disease (IBD) could be considered at high risk for COVID-19 if they are being treated with immunosuppressive agents, according to Ryan Ungaro, MD, of Icahn School of Medicine at Mount Sinai in New York City, and colleagues writing in Clinical Gastroenterology and Hepatology.
Recently, several GI societies, led by the American Gastroenterological Association, released joint clinical insights for gastroenterologists, noting "recent evidence suggesting the potential for coronavirus transmission through droplets and perhaps fecal shedding," posing a risk during endoscopy and colonoscopy procedures.
Minor inflammatory changes and an increase in fatty deposits in the liver
I agree with the findings stated in this article
https://www.researchgate.net/deref/https%3A%2F%2Fwww.jcehepatology.com%2Farticle%2FS0973-6883(20)30027-X%2Ffulltext
The most common finding is an increase moderate in the value of both transaminases
You can find the answer to this question in our article
Article Gastrointestinal and Liver Manifestations of COVID-19